DefenCath® (taurolidine and heparin) catheter lock solution is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.

Matt David, M.D.

Matt David was appointed Executive Vice President and Chief Financial Officer in May 2020 and also served as CorMedix’s interim CEO from October 2021 to May 2022. He leads the company’s finance and investor relations activities. Prior to joining CorMedix, Dr. David was Head of Strategy at Ovid Therapeutics and spent the majority of his career in healthcare investment banking roles where he advised life sciences companies on a broad range of financing and strategic transactions. Earlier in his career, Dr. David spent time as a research analyst covering the pharma sector. Dr. David received his M.D. from NYU School of Medicine and his undergraduate degree from Dartmouth College.